Stem Cell Drugs
As a pharmaceutical company originating hundreds of years ago, Jiuzhitang set its sight on the future and made the strategic arrangement of developing China’s stem cell sector: reconfiguring the landscape of regenerative medicine by giving full play to company’s strength as a player in the Traditional Chinese Medicine industry and leveraging leading global stem cell technologies. This endeavor aims at pioneering a path of innovation suitable for China’s time-honored pharmaceutical businesses by integrating traditional Chinese medical science with the cutting-edge biotechnology in development and production of stem cell products.
Initiated by Jiuzhitang Co., Ltd., Yonghe Qihang Fund founded Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. (“Jiuzhitang Maker”) in March 2018 with an investment amounting to 200 million yuan. Jiuzhitang Maker is a biotechnology company focused on the manufacture, R&D and sales of stem cell-based drugs and regenerative care products.
Jiuzhitang Maker built a large-scale allogenic stem cells R&D and manufacturing facility that meets Chinese, US and EU cGMP standards in ZGC Biomedicine Industry Park, Daxing District, the first of its kind in Beijing. The facility is capable of manufacturing clinical grade stem cell products compliant with Chinese and US drug application requirements.
Food is Drug
In China, diet therapy has proven to be an effective method in disease prevention since ancient times. To address people’s needs for preserving health through diets, Jiuzhitang advocates the practice of improving wellness by eating healthy foods, a concept taking the health-preservation and food cultures promoted in the Inner Cannon of the Yellow Emperor as the core. Accordingly, the company is making proactive efforts to build a comprehensive health products portfolio featuring the idea of “Food is Medicine”.